Silent clues in blood: Proteomic approach for Alzheimer's disease.

CSF proteomics and machine learning reveal distinct stages across the Alzheimer’s disease continuum

These findings uncover protein signatures that reflect underlying AD biology and provide a foundation for stage-specific biomarkers and therapeutic targeting, with important implications for patient stratification and personalized intervention strategies.

Circulating biochemical signatures of neurodegeneration in Alzheimer's disease.

The blood-based biomarkers represent a transformative step toward early diagnosis, large-scale screening, and precision medicine in AD, with significant potential for the development of disease-modifying therapies.

Blood-based emerging biomarkers in early detection and diagnosis of Alzheimer's disease.

The current status of research on blood biomarkers for AD and associated neurodegenerative dementias is updated in this chapter.

The emerging landscape of circulatory biomarkers in Alzheimer's disease.

This chapter explores the pathophysiology of Alzheimer's Disease to identify peripheral molecular markers associated with these early events and facilitate the development of combinatorial therapies.

Redefining Alzheimer's disease diagnostics in the age of blood-based biomarkers.

Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders.